Skip to main content
Top
Published in: Journal of Nuclear Cardiology 4/2023

23-02-2023 | Heart Failure | BRIEF REPORT

Diagnostic performance characteristics of planar quantitative and semi-quantitative parameters of Tc99m pyrophosphate (PYP) imaging for diagnosis of transthyretin (ATTR) cardiac amyloidosis: the SCAN-MP study

Authors: Shivda Pandey, MBBS, FASNC, Sergio Teruya, MD, Carlos Rodriguez, Albert Deluca, MD, Mona Kinkhabwala, MD, Lynne L. Johnson, MD, Denise Fine, MS, Natalia Sabogal, Morgan Winburn, Michelle Castillo, Ketan Bhatia, Rita Malkovskaya, Farbod Raiszadeh, MD, PhD, Damian Kurian, MD, Edward J. Miller, MD, PhD, Andrew J. Einstein, MD, PhD, MASNC, Mathew S. Maurer, MD, Frederick L. Ruberg, MD

Published in: Journal of Nuclear Cardiology | Issue 4/2023

Login to get access

Abstract

Background

The optimal heart-to-contralateral chest (H/CL) ratio threshold for non-invasive diagnosis of transthyretin cardiac amyloidosis (ATTR-CA) using Tc99m pyrophosphate (PYP) imaging in a population with low pretest probability is not known.

Methods

Using myocardial PYP retention by SPECT as the reference standard, we evaluated the diagnostic performance of different semi-quantitative and quantitative (H/CL chest ratio) planar parameters obtained from 3-hour PYP imaging in a prospectively recruited cohort of minority older adults with heart failure and increased LV wall thickness.

Results

Of 229 patients, 14 were found to have ATTR-CA (6.1%). No PYP uptake (grade 0) was observed in 77% of scans, all grade 3 scans were ATTR-CA, and only 4 of 11 (36%) grade 2 scans were ATTR-CA. An H/CL threshold of ≥ 1.4 maximized specificity (99%) and positive predictive value (93%) but resulted in decreased sensitivity (93%), compared to the ≥ 1.3 threshold which had 100% sensitivity.

Conclusion

Among patients with a low pretest likelihood of ATTR-CA, planar interpretation, while useful to exclude disease, must be interpreted with caution. H/CL ratio threshold of ≥ 1.3 resulted in clinically important misclassifications. These data suggest that quantitative planar imaging thresholds may not be appropriate to apply in low pretest likelihood populations being evaluated for ATTR-CA.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol 2019;73:2872‐91.CrossRefPubMedPubMedCentral Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol 2019;73:2872‐91.CrossRefPubMedPubMedCentral
2.
go back to reference Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133:2404‐12.CrossRefPubMed Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133:2404‐12.CrossRefPubMed
3.
go back to reference Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2-diagnostic criteria and appropriate utilization. Circ Cardiovasc Imaging 2021;14:e000030.PubMed Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2-diagnostic criteria and appropriate utilization. Circ Cardiovasc Imaging 2021;14:e000030.PubMed
4.
go back to reference Castano A, Haq M, Narotsky DL, Goldsmith J, Weinberg RL, Morgenstern R, et al. Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: Predicting survival for patients with ATTR cardiac amyloidosis. JAMA Cardiol 2016;1:880‐9.CrossRefPubMed Castano A, Haq M, Narotsky DL, Goldsmith J, Weinberg RL, Morgenstern R, et al. Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: Predicting survival for patients with ATTR cardiac amyloidosis. JAMA Cardiol 2016;1:880‐9.CrossRefPubMed
5.
go back to reference Brenner H, Gefeller O. Variation of sensitivity, specificity, likelihood ratios and predictive values with disease prevalence. Stat Med 1997;16:981‐91.CrossRefPubMed Brenner H, Gefeller O. Variation of sensitivity, specificity, likelihood ratios and predictive values with disease prevalence. Stat Med 1997;16:981‐91.CrossRefPubMed
6.
go back to reference Ransohoff DF, Feinstein AR. Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. N Engl J Med 1978;299:926‐30.CrossRefPubMed Ransohoff DF, Feinstein AR. Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. N Engl J Med 1978;299:926‐30.CrossRefPubMed
7.
go back to reference Masri A, Bukhari S, Ahmad S, Nieves R, Eisele YS, Follansbee W, et al. Efficient 1-hour technetium-99 m pyrophosphate imaging protocol for the diagnosis of transthyretin cardiac amyloidosis. Circ Cardiovasc Imaging 2020;13:e010249.CrossRefPubMedPubMedCentral Masri A, Bukhari S, Ahmad S, Nieves R, Eisele YS, Follansbee W, et al. Efficient 1-hour technetium-99 m pyrophosphate imaging protocol for the diagnosis of transthyretin cardiac amyloidosis. Circ Cardiovasc Imaging 2020;13:e010249.CrossRefPubMedPubMedCentral
9.
go back to reference Poterucha TJ, Elias P, Bokhari S, Einstein AJ, DeLuca A, Kinkhabwala M, et al. Diagnosing transthyretin cardiac amyloidosis by technetium Tc 99m pyrophosphate: A test in evolution. JACC Cardiovasc Imaging 2021;14:1221‐31.CrossRefPubMed Poterucha TJ, Elias P, Bokhari S, Einstein AJ, DeLuca A, Kinkhabwala M, et al. Diagnosing transthyretin cardiac amyloidosis by technetium Tc 99m pyrophosphate: A test in evolution. JACC Cardiovasc Imaging 2021;14:1221‐31.CrossRefPubMed
10.
go back to reference Scully PR, Morris E, Patel KP, Treibel TA, Burniston M, Klotz E, et al. DPD quantification in cardiac amyloidosis: A novel imaging biomarker. JACC Cardiovasc Imaging 2020;13:1353‐63.CrossRefPubMedPubMedCentral Scully PR, Morris E, Patel KP, Treibel TA, Burniston M, Klotz E, et al. DPD quantification in cardiac amyloidosis: A novel imaging biomarker. JACC Cardiovasc Imaging 2020;13:1353‐63.CrossRefPubMedPubMedCentral
11.
go back to reference Ramsay SC, Lindsay K, Fong W, et al. Tc-HDP quantitative SPECT/CT in transthyretin cardiac amyloid and the development of a reference interval for myocardial uptake in the non-affected population. Eur J Hybrid Imaging 2018;2:17.CrossRefPubMed Ramsay SC, Lindsay K, Fong W, et al. Tc-HDP quantitative SPECT/CT in transthyretin cardiac amyloid and the development of a reference interval for myocardial uptake in the non-affected population. Eur J Hybrid Imaging 2018;2:17.CrossRefPubMed
12.
go back to reference Dorbala S, Park MA, Cuddy S, Singh V, Sullivan K, Kim S, et al. Absolute quantitation of cardiac 99mTc-pyrophosphate using cadmium-zinc-telluride-based SPECT/CT. J Nucl Med 2021;62:716‐22.CrossRefPubMedPubMedCentral Dorbala S, Park MA, Cuddy S, Singh V, Sullivan K, Kim S, et al. Absolute quantitation of cardiac 99mTc-pyrophosphate using cadmium-zinc-telluride-based SPECT/CT. J Nucl Med 2021;62:716‐22.CrossRefPubMedPubMedCentral
Metadata
Title
Diagnostic performance characteristics of planar quantitative and semi-quantitative parameters of Tc99m pyrophosphate (PYP) imaging for diagnosis of transthyretin (ATTR) cardiac amyloidosis: the SCAN-MP study
Authors
Shivda Pandey, MBBS, FASNC
Sergio Teruya, MD
Carlos Rodriguez
Albert Deluca, MD
Mona Kinkhabwala, MD
Lynne L. Johnson, MD
Denise Fine, MS
Natalia Sabogal
Morgan Winburn
Michelle Castillo
Ketan Bhatia
Rita Malkovskaya
Farbod Raiszadeh, MD, PhD
Damian Kurian, MD
Edward J. Miller, MD, PhD
Andrew J. Einstein, MD, PhD, MASNC
Mathew S. Maurer, MD
Frederick L. Ruberg, MD
Publication date
23-02-2023
Publisher
Springer International Publishing
Published in
Journal of Nuclear Cardiology / Issue 4/2023
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI
https://doi.org/10.1007/s12350-023-03203-9

Other articles of this Issue 4/2023

Journal of Nuclear Cardiology 4/2023 Go to the issue